Prostate cancer has the second highest incidence of all cancers in males worldwide, with 1,111,700 new cases and 307,500 deaths estimated to have occurred in 2012 [@b1]. Incidence of prostate cancer varies across different geographic regions, with a greater prevalence in Western countries (i.e., the United States and Western Europe) than in Asian countries (i.e., China and Japan)[@b2]. However, in the past decade, the largest increase in incidence was seen for cancer of the prostate in China[@b3]. Age, race/ethnicity, and family history of prostate cancer are the most definitive risk factors for prostate cancer[@b4]. Unhealthy behaviors (i.e., lack of physical activity[@b5]) and eating too few vegetables (i.e., carrots[@b6] and cruciferous vegetables[@b7]) also have been reported to be associated with prostate cancer risk, although controversies still exist.

Recently, several researchers have explored whether hypertension is a potential risk factor for prostate cancer with conflicting results. Two case--control studies and two cohort studies[@b8][@b9][@b10][@b11] suggested that individuals with hypertension had an increased risk of prostate cancer compared with subjects without hypertension. In contrast, several other studies[@b12][@b13][@b14] failed to demonstrate a positive correlation between hypertension and prostate cancer risk. Stocks *et al*.[@b15] even reported a significantly negative association between them. Given the conflicting results as discussed above, we conducted this meta-analysis to summarize evidence on the relationship between hypertension and the risk of prostate cancer.

Results
=======

Literature search and study characteristics
-------------------------------------------

The detailed process of literature search is presented in [Fig. 1](#f1){ref-type="fig"}. 21 published studies[@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28] were eventually included in this meta-analysis of the association between hypertension and prostate cancer risk. These studies (14 cohort, 3 nested case-control and 4 case-control studies) were carried out in the following geographical regions: Europe (n = 9), America (n = 8), and Asia (n = 4). All of the included studies were published between 1997 and 2015, including a total of 24,366 cases. Information on exposure (hypertension) and outcome (prostate cancer) was mainly gained from physical examination and cancer registry, respectively. The scores of study quality, evaluated by the Newcastle-Ottawa Scale (NOS), ranged from 4 to 8 (with a mean of 6.1). [Table 1](#t1){ref-type="table"} lists the general characteristics of all studies included in the present meta-analysis.

Overall analysis and evaluation of heterogeneity
------------------------------------------------

The multivariable-adjusted relative risks (RRs) for each individual study and for the combination of all included studies are presented in [Fig. 2](#f2){ref-type="fig"}. A significant increase in the risk of prostate cancer (RR 1.08, 95% confidence interval (CI) 1.02--1.15, *P* = 0.014) was observed among individuals with hypertension. There was statistically significant heterogeneity among included studies (*P* \< 0.001 for heterogeneity, *I*^*2*^ = 72.1%).

Subgroup analysis
-----------------

Next, we performed stratified analyses by geographical region, study design, study quality, and number of cases ([Table 2](#t2){ref-type="table"}). In the subgroup analysis based on geographical region, more pronounced association was detected in studies from Asia (RR 1.88, 95% CI 1.04--3.38) compared with studies from Europe (RR 1.04, 95% CI 0.97--1.11) and America (RR 1.11, 95% CI 0.97--1.27). When further stratified by study design, the RRs (95% CI) were 1.05 (0.99-1.11) and 1.49 (1.00--2.22) for cohort/nested case-control and case-control studies, respectively. Finally, in the stratified analyses by study quality and number of included cases, statistically significant associations were observed in those studies with high quality (RR 1.16, 95% CI 1.01--1.33) and small sample size (RR 1.15, 95% CI 1.03--1.29) rather than in studies with low quality (RR 1.06, 95% CI 0.98--1.15) or large sample size (RR 1.06, 95% CI 0.95--1.20).

Sensitivity analysis
--------------------

The influence of each study on the pooled RR was evaluated by repeating the overall analysis after omitting each study in turn. The results indicated that no single study dominated the combined RR. The 21 study-specific RRs ranged from a low of 1.06 (95% CI 1.00--1.12) to a high of 1.13 (95% CI 1.03--1.24) via omission of the study by Beebe-Dimmer *et al*.[@b10] and the study by Lund Håheim *et al*.[@b24], respectively ([Fig. 3](#f3){ref-type="fig"}).

Cumulative meta-analysis
------------------------

Cumulative meta-analysis is the process of repeated pooling of individual studies each time adding a new study. In this meta-analysis, we carried out the cumulative meta-analysis according to publication year. As shown in [Fig. 4](#f4){ref-type="fig"}, the combined RR achieved statistical significance when the study by Bhindi *et al*.[@b17] completed in 2015 was added.

Publication bias
----------------

There was no obvious evidence of significant publication bias by Begg's test (*P* = 0.174) or Egger's test (*P* = 0.277).

Discussion
==========

This systematic review and meta-analysis summarized the findings of observational studies on the association between hypertension and prostate cancer risk, including 17 cohort/nested case-control studies and 4 case-control studies. The results indicated that individuals with hypertension had a significant increased risk of prostate cancer.

The findings of this meta-analysis were in agreement with a previous meta-analysis[@b29], which indicated that hypertension was associated with a significant 15% (*P* = 0.035) greater risk of prostate cancer. However, that pooled analysis only included 10 published studies, with a total of 4,343 cases. By contrast, the present meta-analysis included more recent studies and thereby had larger sample size (a total of 24,366 cases); potentially improved statistical power.

The exact mechanism underlying the positive association between hypertension and prostate cancer risk is not clear. It has been proposed that hypertension could increase the risk of prostate cancer through the activity of the sympathetic nervous system that can lead to androgen-mediated stimulation of prostate cancer cell growth[@b18]. In studies with hypertensive animal models, hypertension can result in abnormal proliferation and a defective growth stimulatory-inhibitory control[@b30]. On the other hand, individuals using renin-angiotensin system (RAS) inhibitors, an antihypertensive drug, have been reported to be associated with a reduced risk of prostate cancer (RR 0.92, 95% CI 0.87--0.98)[@b31].

Our study had several strengths. A total of 21 published studies with 24,366 prostate cancer cases were pooled in this meta-analysis, which might enhance the statistical power of the data analysis and thus provide more reliable estimates. Various stratified analyses and sensitivity analyses were performed to explore the sources of heterogeneity and assess the robustness of the combined risk estimate. The estimates for the most fully adjusted model reported in each study were extracted in this study to reduce the potential confounding effect.

There were also several important limitations that need to be considered in interpreting the results of this study. First, substantial heterogeneity was observed across individual studies (*P* \< 0.001 for heterogeneity, *I*^*2*^ = 72.1%), which might distort the combined estimates. Heterogeneity is caused by variation in definitions and ranges of exposure, methods of exposure and outcome assessment, and population sources. Heterogeneity could also be attributed to the heterogeneity of the prostate cancer disease and the divergent results between hypertension and prostate cancer diagnosis and death[@b15]. Second, although Begg's and Egger' test did not show any evidence of publication bias, some inevitable publication bias might exist. Small negative studies were less likely to be published and gray literature, due to its diverse origins and unpublished nature, may be difficult to find. Third, a meta-analysis is unable to solve problems with confounding factors that could be inherent in the original studies. Although the majority of included studies adjusted for a wide range of potential confounders for prostate cancer, residual or unknown confounding variables cannot be completely excluded as a potential interpretation for the findings of current meta-analysis. Inadequate control of all known confounding variables may bias the pooled risk estimate, toward exaggeration or underestimation of effect size. Fourth, the cutoff points for the high and low blood pressure groups were various in included studies, which might contribute to the heterogeneity and have an influence on the summary risk estimate. Fifth, this study lacked the data of tumor characteristics. Prostate cancer is a heterogeneous disease and thus prostate cancer patients have very different characteristics, progression and survival. Lastly, subjects with hypertension are under increased medical monitoring, which can cause detection bias, especially after PSA screening was introduced in the early 1990s. A large proportion of PSA-detected cancers have been low-risk tumors, which may dilute an association between metabolic factors and high risk tumors[@b32].

Conclusion
==========

This meta-analysis indicates that hypertension may be associated with an increased risk of prostate cancer. Considering the substantial heterogeneity and residual confounding among included studies, further large-scale, well-designed prospective cohorts, as well as mechanistic studies, are urgently needed to confirm our preliminary findings.

Materials and Methods
=====================

Literature search
-----------------

A comprehensive literature search of published studies was performed in January 2016 based on PubMed, Web of Science, and the Chinese National Knowledge Infrastructure (CNKI) databases with the following search algorithm: ("hypertension" or "blood pressure" or "systolic pressure" or "diastolic pressure") and ("prostate cancer" or "prostate neoplasm") and ("cohort" or "case control" or "case-control"). In addition, the lists of references from retrieved articles and reviews were also checked to identify any additional eligible studies. No limitations on language or publication date were applied. This systematic review and meta-analysis was designed, performed, and reported based on the standards of quality for reporting meta-analyses[@b33].

Study selection
---------------

A study was included in this meta-analysis if it met all of the following criteria: (*i*) the exposure of interest was hypertension; Hypertension is defined as a systolic blood pressure above 140 mmHg or a diastolic blood pressure above 90 mmHg. (*ii*) the outcome of interest was prostate cancer; (*iii*) study design was cohort, nested case-control or case-control; and (*iv*) the risk estimates with their corresponding 95% CIs were available (or enough data were provided to estimate effect size). If multiple publications reported data from the same study, the publication with the largest sample size was included in the meta-analysis.

Quality assessment
------------------

Two investigators (Z.L. and X.X.) assessed the quality of each study independently by using the NOS (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). NOS is an eight-item instrument designed to assess selection (four items), comparability (one item), and exposure/outcome (three items). Each item represents one point, except for comparability (two points). Thus the range of potential scores is 0--9 points. A study is classified as high quality if the score is 7--9 points.

Data extraction
---------------

The following information were gained from each study: first author's name, publication date, geographical region, study design, age, number of cases, method of exposure and outcome assessment, adjusted risk estimates with their corresponding 95% CIs, and matched or adjusted variables in the design or statistical analysis. Information was collected independently by two authors (Z.L. and X.X.) and any discrepancies were subject to discussion.

Statistical methods
-------------------

According to rare disease assumption, the OR (odds ratio) was assumed approximately the same as RR, and the RR was designated as the study outcome. RRs and their 95% CIs were used to calculate and assess the strength of the relationship between hypertension and prostate cancer risk. A random-effects model reported by DerSimonian and Laird[@b34], which consider both between-study and within-study variability, was applied to estimate the pooled RR and its 95% CI. Stratified analyses were conducted based on geographical region, study design, study quality, and number of cases.

Cochran *Q* and the *I*^*2*^ index[@b35] were adopted to evaluate the heterogeneity of RRs among the included studies. The level of significancefor Cochrane *Q* was set to 0.1 (10%). The value of *I*^*2*^ was used to describe the degree of heterogeneity (*I*^*2*^ \< 25%: no heterogeneity; *I*^*2*^ = 25--50%: moderate heterogeneity; *I*^*2*^ \> 50%: large or extreme heterogeneity).

Sensitivity analysis was conducted by omitting each study in turn and recalculating the combined RR to determine the influence of each study on the overall risk estimate. Cumulative meta-analysis was also performed by sorting the studies according to publication date.

Begg's test (rank correlation method)[@b36] and Egger's test (linear regression method)[@b37] were applied to evaluate the potential publication bias. All of the statistical analyses were completed using STATA 11.0 (StataCorp, College Station, TX), using two-sided *P* values (set at 0.05).
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###### Characteristics of the studies included in meta-analysis of association between hypertension status and prostate cancer risk.

  Study                    Year   Region       Study design       No. of cases       Age (yr)        Exposure assessment       Outcome assessment                                                          Matched or adjusted factors                                                        NOS score
  ----------------------- ------ --------- --------------------- -------------- ------------------ ----------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------- -----------
  Su *et al*.              2015   Taiwan    Nested case-control        74        54.87 (SD 18.69)         Database                  Database                                                        Age, sex, residence, and insurance premium                                                    7
  Bhindi *et al*.          2015   Canada          Cohort             2,235             64.9              Measurement                 Biopsy              Age, ethnicity, family history of prostate cancer, prostate volume, history of any prior biopsy, and 5a-reductase inhibitor use          8
  Pai *et al*.             2015   Taiwan          Cohort             1,971       69.31 (SD 9.31)          Database                  Database                                                      Age, income, urbanization level, and index day                                                  7
  Romero *et al*.          2012   Brazil          Cohort               58              ≥40               Measurement                 Biopsy                                                                            Age                                                                        5
  Ganesh *et al*.          2011    India       Case-control           123               64              Questionnaire        Histologically proven                                                         Age, religion, and education                                                           4
  Pelucchi *et al*.        2011    Italy       Case-control          1,294         66 (46--74)          Self-reported       Histologically confirmed   Age, study center, education, smoking, alcohol, physical activity, family history of prostate cancer, and nonalcoholic energy intake       7
  Wallner *et al*.         2011     US            Cohort              206             40--79         Physician-diagnosed             Biopsy                                                                            Age                                                                        6
  Grundmark *et al*.       2010   Sweden          Cohort              237               NA               Measurement                Database                                                                            NA                                                                        5
  Martin *et al*.          2010   Norway          Cohort             1,974        50.3 (SD 15.2)    Physical examination        Cancer registry                      Age, height, BMI, smoking, marital status, education, physical activity, diabetes, and country of origin                     8
  Stocks *et al*.          2010   Sweden          Cohort             10,002       70.1 (SD 8.4)      Health examination         Cancer registry                                                               Age, smoking, and BMI                                                               7
  Beebe-Dimmer *et al*.    2009     US         Case-control           637               62             Medical records              Database                                                Age, PSA screening, diabetes, BMI, HDL, and triglycerides                                             6
  Inoue *et al*.           2009    Japan          Cohort               86             40--69             Measurement            Cancer registry                                          Age, study area, smoking, ethanol intake, and serum cholesterol                                          7
  Beebe-Dimmer *et al*.    2007     US         Case-control           139             40--79            Questionnaire           Cancer registry                                                              Age and smoking history                                                              7
  Tuohimaa *et al*.        2007   Finland   Nested case-control       132         62.1 (SD 4.9)          Measurement            Cancer registry                                                                     Vitamin D                                                                     5
  Lund Håheim *et al*.     2006   Norway          Cohort              507             40--49            Questionnaire           Cancer registry                                                                        Age                                                                        5
  Tande *et al*.           2006     US            Cohort              385             45--64        Clinical examination        Cancer registry                           Age, race, family history, education, smoking, ethanol intake, caloric intake, and milk intake                          6
  Ronquist *et al*.        2004     UK      Nested case-control      1,013            50--79              Database               Medical record                                    Age, smoking, BMI, alcohol, diabetes, IHD, HF, prostatism and calendar year                                    6
  Fitzpatrick *et al*.     2001     US            Cohort              209              ≥65          Clinical examination         Medical record                                                                 Age, race, and BMI                                                                6
  Rosengren *et al*.       1998   Sweden          Cohort              263             47--55        Screening examination       Cancer registry                                                                        Age                                                                        5
  Friedman *et al*.        1997     US            Cohort             2,297            30--79           Health checkup           Cancer registry                                                      Age, race, BMI, and alcohol consumption                                                      7
  Tulinius *et al*.        1997   Iceland         Cohort              524          50.3 (SD 11)         Questionnaire           Cancer registry                                                                        Age                                                                        5

PSA, prostate-specific antigen; NOS, Newcastle-Ottawa Scale; yr, year; SD, standard deviation; BMI, body mass index; IHD, ischemic heart disease; HF, heart failure; HDL, high density lipoprotein; NA, not available.

###### Subgroup analyses of the association between hypertension and prostate cancer risk.

  Subgroup                       Included studies   No. of cases   Pooled RR (95% CI)    *P*    Heterogeneity         
  ----------------------------- ------------------ -------------- -------------------- ------- --------------- ------ ---------
  Total                                 21                         1.08 (1.02--1.15)    0.014       71.70       72.1   \<0.001
  Study design                                                                                                        
   Cohort/nested case-control           17             22,173      1.05 (0.99--1.11)    0.115       50.30       68.2   \<0.001
   Case-control                         4              2,193       1.49 (1.00--2.22)    0.050       13.31       77.5    0.004
  Geographical region                                                                                                 
   America                              8              6,166       1.11 (0.97--1.27)    0.121       14.70       52.4    0.040
   Europe                               9              15,946      1.04 (0.97--1.11)    0.245       37.13       78.5   \<0.001
   Asia                                 4              2,254       1.88 (1.04--3.38)    0.036       9.38        68.0    0.025
  Study quality                                                                                                       
   High (NOS ≥ 7)                       9              20,072      1.16 (1.01--1.33)    0.039       49.64       83.9   \<0.001
   Low (NOS \<7)                        12             4,294       1.06 (0.98--1.15)    0.124       16.25       32.3    0.132
  No. of cases                                                                                                        
   ≥1000                                7              20,786      1.06 (0.95--1.20)    0.303       32.81       81.7   \<0.001
   \<1000                               14             3,580       1.15 (1.03--1.29)    0.014       31.03       58.1    0.003

No., number; RR, relative risk; CI, confidence interval; NOS, Newcastle-Ottawa Scale.
